Susceptibility of Influenza Viruses to the Novel Cap-Dependent Endonuclease Inhibitor Baloxavir Marboxil

The novel cap-dependent endonuclease inhibitor baloxavir marboxil was approved for the treatment of influenza A and B virus infections in February 2018 in Japan. Because of the need to monitor influenza viruses for reduced susceptibility to this drug, we used two cell-based screening systems – a con...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Emi Takashita, Hiroko Morita, Rie Ogawa, Kazuya Nakamura, Seiichiro Fujisaki, Masayuki Shirakura, Tomoko Kuwahara, Noriko Kishida, Shinji Watanabe, Takato Odagiri
Formato: Artigo
Idioma:Inglês
Publicado em: Frontiers Media S.A. 2018-12-01
Colecção:Frontiers in Microbiology
Assuntos:
influenza virus
cap-dependent endonuclease inhibitor
baloxavir marboxil
baloxavir acid
S-033188
neuraminidase inhibitors
Acesso em linha:https://www.frontiersin.org/article/10.3389/fmicb.2018.03026/full
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados